In vitro susceptibilities of Rickettsia rickettsii and Rickettsia conorii to roxithromycin and pristinamycin.
In vitro susceptibilities of Rickettsia rickettsii and Rickettsia conorii to roxithromycin, pristinamycin, and the pristinamycin compounds, P1 and P2, were determined by a dye uptake assay and a plaque assay. The MICs were 1 microgram/ml for roxithromycin, 2 micrograms/ml for pristinamycin, greater than 256 micrograms/ml for P1, and 2 micrograms/ml for P2. Compounds P1 and P2 did not share synergetic activity. The toxicity of each compound was determined by a dye uptake assay. Toxic concentrations were 128 micrograms/ml for roxithromycin, 32 micrograms/ml for pristinamycin, greater than 256 micrograms/ml for P1, and 32 micrograms/ml for P2. Roxithromycin and pristinamycin could be useful in the treatment of Rocky Mountain spotted fever and Mediterranean spotted fever.
Drancourt
M
M
Centre National de Référence des Rickettsioses, Centre Hospitalier Universitaire Timone, Marseille, France.
Raoult
D
D
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000633:toxicity; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000494:pharmacology / Q000633:toxicity; D012281:Rickettsia / Q000187:drug effects*; D012284:Rickettsia rickettsii / Q000187:drug effects*; D015575:Roxithromycin / Q000494:pharmacology* / Q000633:toxicity; D014709:Vero Cells / Q000187:drug effects; D014769:Virginiamycin
D000900:Anti-Bacterial Agents; D010456:Peptides, Cyclic; D014769:Virginiamycin; D015575:Roxithromycin